Micro
Emerging
Active
Morgan Stanley boosts GILD outlook on updated biopharma models
New narrative with limited coverage — still forming.
Score
0.2
Velocity
▲ 0.0
Articles
4
Sources
1
Sentiment Timeline
Event Timeline
May 21, 2026
Morgan Stanley Reassesses Gilead Sciences (GILD) Outlook Following Quarterly Report
Neutral
🤖
AI Overview
What happened: On April 10 and 13, Morgan Stanley and Citi respectively raised their price targets for Gilead Sciences (GILD) to $175 and $165, maintaining Overweight and Buy ratings. Morgan Stanley updated its biopharma models, while Citi looked ahead to Gilead's Q1 biopharma preview. Jim Cramer also endorsed Gilead on Mad Money, citing CEO Daniel O'Day's initiatives.
Market impact: The bullish outlook from these prominent financial institutions drove GILD's stock price up. This positively impacts the biopharma sector, with Gilead's high dividend yield also attracting income-oriented investors.
What to watch next: Gilead's Q1 earnings report on May 4 will provide insights into its biopharma business, potentially validating or revising analysts' optimism. Additionally, any updates on Gilead's pipeline, including its COVID-19 treatment remdesivir and HIV therapies, will be crucial to monitor.
Market impact: The bullish outlook from these prominent financial institutions drove GILD's stock price up. This positively impacts the biopharma sector, with Gilead's high dividend yield also attracting income-oriented investors.
What to watch next: Gilead's Q1 earnings report on May 4 will provide insights into its biopharma business, potentially validating or revising analysts' optimism. Additionally, any updates on Gilead's pipeline, including its COVID-19 treatment remdesivir and HIV therapies, will be crucial to monitor.
AI Overview as of Apr 19, 2026
Timeline
Last UpdatedApr 15, 2026